ChromaCode and Protean to launch assay for lung cancer in US


Medical Device Network:

HDPCR is an advanced method for multiplexing biomarkers in a single, rapid assay across multiple sample types. ChromaCode has entered a strategic partnership with Protean BioDiagnostic for the launch of a non-small cell lung cancer (NSCLC) assay in the US.

To be available through an early access programme, the assay leverages ChromaCode’s High Definition PCR (HDPCR) multiplexing technology.

View full article

More Articles Here